1-anilino-8-naphthalenesulfonate has been researched along with Wet Macular Degeneration in 3 studies
1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd
8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.
Wet Macular Degeneration: A form of RETINAL DEGENERATION in which abnormal CHOROIDAL NEOVASCULARIZATION occurs under the RETINA and MACULA LUTEA, causing bleeding and leaking of fluid. This leads to bulging and or lifting of the macula and the distortion or destruction of central vision.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Fernández-Vega, B | 1 |
García, M | 1 |
Olivares, L | 1 |
Álvarez, L | 1 |
González-Fernández, A | 1 |
Artime, E | 1 |
Fernández-Vega Cueto, A | 1 |
Cobo, T | 1 |
Coca-Prados, M | 1 |
Vega, JA | 1 |
González-Iglesias, H | 1 |
Lin, LY | 1 |
Zhou, Q | 1 |
Hagstrom, S | 1 |
Maguire, MG | 2 |
Daniel, E | 2 |
Grunwald, JE | 1 |
Martin, DF | 2 |
Ying, GS | 2 |
Jaffe, GJ | 1 |
Toth, CA | 1 |
Grunwald, J | 1 |
Hagstrom, SA | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (CATT)[NCT00593450] | Phase 3 | 1,208 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
(NCT00593450)
Timeframe: at 1 Year
Intervention | mm^2 (Mean) |
---|---|
1-Lucentis Monthly | 6.6 |
2-Avastin Monthly | 6.5 |
3-Lucentis as Needed | 7.3 |
4-Avastin as Needed | 7.0 |
(NCT00593450)
Timeframe: Baseline and 1 Year
Intervention | mm^2 (Mean) |
---|---|
1-Lucentis Monthly | -0.1 |
2-Avastin Monthly | 0.3 |
3-Lucentis as Needed | 0.6 |
4-Avastin as Needed | 1.3 |
(NCT00593450)
Timeframe: at 1 Year
Intervention | US dollars per patient (Mean) |
---|---|
1-Lucentis Monthly | 23400 |
2-Avastin Monthly | 595 |
3-Lucentis as Needed | 13800 |
4-Avastin as Needed | 385 |
"Visual acuity testing was performed with the Electronic Visual Tester (EVA) following the ETDRS protocol. VA score is measured as number of letters read correctly. The VA score change is the difference of the VA score at 1 Year and the VA score at baseline.~In this study, the outcome VA score change is ranged from -71 to 52, with the higher VA score change the better visual acuity improvement." (NCT00593450)
Timeframe: Baseline and 1 Year
Intervention | No. of Letters (Mean) |
---|---|
1-Lucentis Monthly | 8.5 |
2-Avastin Monthly | 8.0 |
3-Lucentis as Needed | 6.8 |
4-Avastin as Needed | 5.9 |
(NCT00593450)
Timeframe: Baseline and 1 Year
Intervention | mm Hg (Mean) |
---|---|
1-Lucentis Monthly | -0.9 |
2-Avastin Monthly | -1.4 |
3-Lucentis as Needed | -1.9 |
4-Avastin as Needed | -2.1 |
(NCT00593450)
Timeframe: Baseline and 1 Year
Intervention | mm Hg (Mean) |
---|---|
1-Lucentis Monthly | -2.1 |
2-Avastin Monthly | -5.4 |
3-Lucentis as Needed | -5.2 |
4-Avastin as Needed | -4.5 |
Cumulative over the 1 year of trial (NCT00593450)
Timeframe: 1 Year
Intervention | Number of Treatments (Mean) |
---|---|
1-Lucentis Monthly | 11.7 |
2-Avastin Monthly | 11.9 |
3-Lucentis as Needed | 6.9 |
4-Avastin as Needed | 7.7 |
(NCT00593450)
Timeframe: at 1 Year
Intervention | μm (Mean) |
---|---|
1-Lucentis Monthly | 152 |
2-Avastin Monthly | 172 |
3-Lucentis as Needed | 166 |
4-Avastin as Needed | 172 |
(NCT00593450)
Timeframe: Baseline and 1 Year
Intervention | μm (Mean) |
---|---|
1-Lucentis Monthly | -100 |
2-Avastin Monthly | -79 |
3-Lucentis as Needed | -81 |
4-Avastin as Needed | -79 |
(NCT00593450)
Timeframe: at 1 Year
Intervention | μm (Mean) |
---|---|
1-Lucentis Monthly | 266 |
2-Avastin Monthly | 300 |
3-Lucentis as Needed | 294 |
4-Avastin as Needed | 308 |
(NCT00593450)
Timeframe: Baseline and 1 Year
Intervention | μm (Mean) |
---|---|
1-Lucentis Monthly | -196 |
2-Avastin Monthly | -164 |
3-Lucentis as Needed | -168 |
4-Avastin as Needed | -152 |
"Visual acuity testing was performed with the Electronic Visual Tester (EVA) following the ETDRS protocol. VA score is measured as number of letters read correctly.~In this study, the outcome VA score is ranged from 0 to 97, with the higher score the better visual acuity." (NCT00593450)
Timeframe: at 1 Year
Intervention | No. of Letters (Mean) |
---|---|
1-Lucentis Monthly | 68.8 |
2-Avastin Monthly | 68.4 |
3-Lucentis as Needed | 68.4 |
4-Avastin as Needed | 66.5 |
(NCT00593450)
Timeframe: Baseline and 1 Year
Intervention | Participants (Number) | ||||
---|---|---|---|---|---|
Increase of ≥15 letters | Increase of 5-14 letters | Change of ≤4 letters | Decrease of 5-14 letters | Decrease of ≥15 letters | |
1-Lucentis Monthly | 97 | 90 | 62 | 19 | 16 |
2-Avastin Monthly | 83 | 98 | 50 | 18 | 16 |
3-Lucentis as Needed | 71 | 103 | 75 | 23 | 13 |
4-Avastin as Needed | 76 | 90 | 59 | 23 | 23 |
(NCT00593450)
Timeframe: at 1 Year
Intervention | Participants (Number) | ||
---|---|---|---|
Absent | Present | Data missing | |
1-Lucentis Monthly | 167 | 97 | 20 |
2-Avastin Monthly | 153 | 100 | 12 |
3-Lucentis as Needed | 133 | 137 | 15 |
4-Avastin as Needed | 111 | 145 | 15 |
(NCT00593450)
Timeframe: at 1 Year
Intervention | Participants (Number) | ||
---|---|---|---|
Absent | Present | Data missing | |
1-Lucentis Monthly | 124 | 151 | 9 |
2-Avastin Monthly | 69 | 188 | 8 |
3-Lucentis as Needed | 68 | 203 | 14 |
4-Avastin as Needed | 52 | 214 | 5 |
(NCT00593450)
Timeframe: at 1 Year
Intervention | Participants (Number) | ||||
---|---|---|---|---|---|
83-97 letters, 20/12-20 | 68-82 letters, 20/25-40 | 53-67 letters, 20/50-80 | 38-52 letters, 20/100-160 | ≤37 letters, ≤20/200 | |
1-Lucentis Monthly | 42 | 149 | 52 | 23 | 18 |
2-Avastin Monthly | 45 | 134 | 47 | 21 | 18 |
3-Lucentis as Needed | 38 | 141 | 66 | 23 | 17 |
4-Avastin as Needed | 40 | 127 | 57 | 24 | 23 |
1 trial available for 1-anilino-8-naphthalenesulfonate and Wet Macular Degeneration
Article | Year |
---|---|
Single-Nucleotide Polymorphisms Associated With Age-Related Macular Degeneration and Lesion Phenotypes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
Topics: Aged; Aged, 80 and over; Complement C2; Complement C3; Complement Factor B; Complement Factor H; Cro | 2016 |
2 other studies available for 1-anilino-8-naphthalenesulfonate and Wet Macular Degeneration
Article | Year |
---|---|
The association study of lipid metabolism gene polymorphisms with AMD identifies a protective role for APOE-E2 allele in the wet form in a Northern Spanish population.
Topics: Aged; Aged, 80 and over; Alleles; Apolipoprotein E2; Case-Control Studies; Female; Genotype; Humans; | 2020 |
Association of Single-Nucleotide Polymorphisms in Age-Related Macular Degeneration With Pseudodrusen: Secondary Analysis of Data From the Comparison of AMD Treatments Trials.
Topics: Aged; Angiogenesis Inhibitors; Complement C2; Complement C3; Complement Factor B; Complement Factor | 2018 |